Tyche Wealth Partners LLC boosted its holdings in Johnson & Johnson (NYSE:JNJ – Free Report) by 41.2% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 31,618 shares of the company’s stock after purchasing an additional 9,219 shares during the quarter. Johnson & Johnson makes up approximately 1.2% of Tyche Wealth Partners LLC’s holdings, making the stock its 18th biggest position. Tyche Wealth Partners LLC’s holdings in Johnson & Johnson were worth $8,371,000 as of its most recent SEC filing.
A number of other institutional investors have also added to or reduced their stakes in JNJ. Wellington Management Group LLP increased its holdings in shares of Johnson & Johnson by 12.5% in the second quarter. Wellington Management Group LLP now owns 22,588,696 shares of the company’s stock worth $5,736,851,000 after purchasing an additional 2,513,321 shares during the last quarter. Deutsche Bank AG boosted its stake in Johnson & Johnson by 8.5% during the second quarter. Deutsche Bank AG now owns 15,661,323 shares of the company’s stock valued at $3,977,506,000 after buying an additional 1,225,676 shares during the last quarter. Fisher Asset Management LLC grew its holdings in Johnson & Johnson by 11.5% during the 3rd quarter. Fisher Asset Management LLC now owns 14,837,126 shares of the company’s stock valued at $3,927,981,000 after buying an additional 1,530,070 shares in the last quarter. Amundi grew its holdings in Johnson & Johnson by 17.5% during the 1st quarter. Amundi now owns 13,406,820 shares of the company’s stock valued at $3,277,163,000 after buying an additional 2,001,139 shares in the last quarter. Finally, Janus Henderson Group PLC grew its holdings in Johnson & Johnson by 1.9% during the 1st quarter. Janus Henderson Group PLC now owns 7,872,478 shares of the company’s stock valued at $1,924,323,000 after buying an additional 148,497 shares in the last quarter. 69.55% of the stock is owned by hedge funds and other institutional investors.
Johnson & Johnson Trading Down 2.1%
Shares of NYSE JNJ opened at $272.75 on Thursday. Johnson & Johnson has a 1-year low of $199.38 and a 1-year high of $290.25. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.02 and a quick ratio of 0.74. The business’s 50 day moving average is $267.42 and its two-hundred day moving average is $250.61. The stock has a market capitalization of $656.58 billion, a P/E ratio of 41.33, a PEG ratio of 2.75 and a beta of 0.22.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last posted its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.53 by $0.06. The business had revenue of $25.40 billion during the quarter, compared to analyst estimates of $25.38 billion. Johnson & Johnson had a return on equity of 31.64% and a net margin of 16.20%. The company’s revenue for the quarter was up 5.9% on a year-over-year basis. During the same period last year, the company earned $2.80 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, research analysts expect that Johnson & Johnson will post 11.12 EPS for the current year.
Johnson & Johnson Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Investors of record on Tuesday, November 24th will be given a $1.34 dividend. The ex-dividend date is Tuesday, November 24th. This represents a $5.36 dividend on an annualized basis and a yield of 2.0%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 81.21%.
Insiders Place Their Bets
In other Johnson & Johnson news, EVP Elizabeth Forminard sold 13,072 shares of Johnson & Johnson stock in a transaction on Thursday, November 12th. The shares were sold at an average price of $284.39, for a total transaction of $3,717,546.08. Following the completion of the transaction, the executive vice president directly owned 16,994 shares of the company’s stock, valued at $4,832,923.66. The trade was a 43.48% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Timothy Schmid sold 33,597 shares of Johnson & Johnson stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the transaction, the executive vice president directly owned 25,447 shares of the company’s stock, valued at $6,991,308.78. The trade was a 56.90% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 0.16% of the stock is owned by company insiders.
Wall Street Analyst Weigh In
A number of research firms have issued reports on JNJ. Erste Group Bank downgraded Johnson & Johnson from a “buy” rating to a “hold” rating in a research note on Wednesday, October 21st. Johnson Rice downgraded Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Wednesday, October 21st. Raymond James Financial set a $280.00 target price on shares of Johnson & Johnson in a report on Monday, August 3rd. Argus set a $300.00 price target on shares of Johnson & Johnson in a research report on Wednesday, July 29th. Finally, HSBC upped their price target on shares of Johnson & Johnson from $290.00 to $320.00 and gave the company a “buy” rating in a research note on Thursday, September 10th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $275.92.
View Our Latest Analysis on Johnson & Johnson
Top Johnson & Johnson Stories
Here are a few of the latest stories about JNJ:
- Neutral Sentiment: Recent coverage also highlighted J&J as a long-established dividend payer, which supports its appeal to income-focused investors but offers little new company-specific information about near-term earnings. Article: Reliable Retirement Income Dividend Stocks
- Negative Sentiment: A Louisiana appeals court upheld a multimillion-dollar mesothelioma verdict against J&J related to talc in its baby powder, renewing concern about litigation exposure. Article: Louisiana Appeals Court Upholds Damages in Mesothelioma Case
- Negative Sentiment: Recent coverage also associated a prior decline in JNJ shares with insider selling, which can add near-term pressure on investor sentiment. Article: JNJ Stock Price Down Following Insider Selling
About Johnson & Johnson
Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.
Read More
- Five stocks we like better than Johnson & Johnson
- From Berlin to Brussels: Tesla’s $3.3 Billion Robotaxi Gamble
- Target Stock Is Up Over 70%—Has the Easy Money Already Been Made?
- Amazon’s Zoox Just Joined Uber—Could That Change the Robotaxi Threat?
- Drilling for Yield in the Gulf: Chevron Drops Anchor in Deepwater
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
